Navigating BCG Shortages in NMIBC

A panel of experts on non–muscle invasive bladder cancer (NMIBC) discuss challenges associated with BCG shortages and the impact on treatment options and patients’ quality of life.

Now Viewing

EP: 1.Navigating BCG Shortages in NMIBC

EP: 2.The Evolving Treatment Landscape in BCG-Unresponsive NMIBC

EP: 3.Efficacy and Safety Data from SunRISe-1

EP: 4.Overview of the QUILT Trial in BCG-Unresponsive NMIBC

EP: 5.Quality of Life and Progression Considerations in BCG-Unresponsive NMIBC

EP: 6.Adverse Effect Management and the Role of Immunotherapy in NMIBC

EP: 7.Selecting Optimal Treatment in BCG-Unresponsive NMIBC

EP: 8.Patient Monitoring Strategies in BCG-Unresponsive NMIBC

EP: 9.Promising Developments in NMIBC

EP: 10.Key Takeaways on the Evolving NMIBC Treatment Landscape

Related Videos

Related Content

Advertisement

May 12th 2025

Disitamab vedotin plus toripalimab extends PFS, OS in HER2-positive la/mUC

Hannah Clarke

The phase 3 RC48-C016 trial met its primary end points.

May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

May 7th 2025

Physical function and frailty measures offer distinct insights in patients with bladder cancer

Hannah Clarke

Data showed that physical function and self-reported frailty assessments were poorly correlated.

May 26th 2022

Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

Urology Times staff

“We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.

May 5th 2025

FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept

Hannah Clarke

The sBLA for NAI was submitted to the FDA in March 2025.

May 1st 2025

FDA updates in urology: April 2025

Hannah Clarke

A recap of the FDA submissions and regulatory decisions in urology from April 2025.

Related Content

Advertisement

May 12th 2025

Disitamab vedotin plus toripalimab extends PFS, OS in HER2-positive la/mUC

Hannah Clarke

The phase 3 RC48-C016 trial met its primary end points.

May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

May 7th 2025

Physical function and frailty measures offer distinct insights in patients with bladder cancer

Hannah Clarke

Data showed that physical function and self-reported frailty assessments were poorly correlated.

May 26th 2022

Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

Urology Times staff

“We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.

May 5th 2025

FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept

Hannah Clarke

The sBLA for NAI was submitted to the FDA in March 2025.

May 1st 2025

FDA updates in urology: April 2025

Hannah Clarke

A recap of the FDA submissions and regulatory decisions in urology from April 2025.